glycerophosphoethanolamine has been researched along with Nerve Degeneration in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biglieri, M; Bisaglia, M; Mancini, F; Milanese, C; Russo, C; Schettini, G; Venezia, V | 1 |
| Blusztajn, JK; Growdon, JH; Logue, M; Lopez Gonzalez-Coviella, I; Wurtman, RJ | 1 |
2 other study(ies) available for glycerophosphoethanolamine and Nerve Degeneration
| Article | Year |
|---|---|
alpha-Glycerylphosphorylethanolamine rescues astrocytes from mitochondrial impairment and oxidative stress induced by amyloid beta-peptides.
Topics: Amyloid beta-Peptides; Animals; Astrocytes; Cell Membrane; Cells, Cultured; Gliosis; Lipid Peroxidation; Membrane Fluidity; Membrane Potentials; Microscopy, Confocal; Mitochondria; Nerve Degeneration; Oxidative Stress; Peptide Fragments; Phosphatidylethanolamines; Rats; Tetrazolium Salts; Thiazoles | 2004 |
Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.
Topics: Aged; Alzheimer Disease; Brain; Down Syndrome; Female; Glycerylphosphorylcholine; Humans; Male; Middle Aged; Nerve Degeneration; Phosphatidylethanolamines | 1990 |